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Abstract: Background and Objective: Urinary tract infections (UTIs) are common in human medicine, 
affecting large patient populations worldwide. The principal cause of UTIs is uropathogenic 
Escherichia coli (UPEC) and Klebsiella, both in community and nosocomial settings. The assessment 
of local data on prevalence and resistance is essential to evaluate trends over time and to reflect on 
the national situation, compared to international data, using the methods of analytical 
epidemiology. Materials and Methods: The aim of this study was to assess resistance trends and 
epidemiology of UTIs caused by E. coli and Klebsiella species in inpatients and outpatients at a 
tertiary-care hospital in Hungary, using microbiological data. To evaluate resistance trends, several 
antibiotics were chosen as indicator drugs, based on local utilization data. Results: E. coli was the 
most prevalent isolate, representing 56.75 ± 4.86% for outpatients and 42.29 ± 2.94% for inpatients. 
For E. coli, the ratio of resistant strains for several antibiotics was significantly higher in the inpatient 
group, while in Klebsiella, similar trends were only observed for gentamicin. Extended-spectrum β-
lactamase (ESBL)-producing isolates were detected in 4.33–9.15% and 23.22–34.22% from 
outpatient, 8.85–38.97% and 10.89–36.06% from inpatient samples for E. coli and Klebsiella, 
respectively. Conclusions: Resistance developments in common UTI pathogens (especially to 
fosfomycin, sulfamethoxazole-trimethoprim, fluoroquinolones, and 3rd generation 
cephalosporins), seriously curb therapeutic options, especially in outpatient settings. 
Keywords: urinary tract infection; infectious disease; antibiotic; resistance; indicator; epidemiology; 
fosfomycin; ESBL; Escherichia coli; Klebsiella 
 
1. Introduction 
Urinary tract infections (UTIs) are some of the most common infections in human medicine, 
affecting a large patient population (around 150 million cases/year) to various extents, irrespective of 
age and gender [1,2]. Both community-acquired (representing 10–30% of infections) and nosocomial 
UTIs (accounting for 25–50% of infections) should be considered as an important factor of morbidity 
(they are often associated with complications, sequelae, recurrence and decreased quality of life), a 
serious public health issue and an economic burden (the therapy and care of these patients alone is 
estimated to cost around 5 billion US$) [3–5]. The causative agents of UTIs are diverse, especially in 
nosocomial settings (where prolonged catheterization and immunosuppression facilitates the 
occurrence of non-conventional urinary pathogens) [6,7]. 
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However, the most common causative agents of UTIs are the members of the Enterobacteriaceae 
family (or the Enterobacterales order, based on recent taxonomic changes [8]), followed by (in 
decreasing order of frequency) some Gram-positive bacteria (Enterococcus faecalis, Group B 
streptococci, Staphylococcus saprophyticus and S. aureus), atypical microorganisms (Mycoplasma, 
Ureaplasma species), non-fermenting Gram-negative bacteria (Pseudomonas, Acinetobacter) and Candida 
spp. [1,3–6,9,10]. The principal cause of UTIs (>80%) are uropathogenic Escherichia coli (UPEC) and 
Klebsiella species (more specifically, K. pneumoniae and K. oxytoca), both in the community and 
nosocomial settings. E. coli is described as the etiological agent in 60–90% of urinary tract infections, 
while Klebsiella species accounts for 3–20% of cases [3,11–15]. These species are successful pathogens 
in the urinary system, as they possess the relevant virulence factors required to successfully survive 
on and adhere to urinary epithelium, cause tissue damage and to ascend to the upper urinary tract 
(leading to complicated UTIs) [16–21]. These virulence factors include the lipopolysaccharide (LPS), 
polysaccharide capsule, outer membrane vesicles, iron-uptake (aerobactin) and siderophore 
receptors, adhesins, Type-1 fimbriae, cytotoxins and urease production. In fact, UPEC may be 
classified into several phylogroups (namely A, B1, B2 and D) based on the presence of pathogenicity 
islands (PAI) and virulence factor expression [16–21]. The relevance of Klebsiella species has been 
described in nosocomial UTIs, as they are ubiquitous in the hospital environment and are able to 
survive on both living (e.g., patient’s skin) and abiotic (e.g., wards, catheters) surfaces [22–24]. 
The recommended drugs for the (empiric) treatment of uncomplicated urinary tract infections 
include nitrofurantoin, fosfomycin and sulfamethoxazole/trimethoprim (if local resistance levels do 
not exceed 20%), which are all available per os; in case of resistance or hypersensitivity to these drugs, 
or if complicated UTIs (e.g., pyelonephritis) need to be treated, other therapeutic options, such as β-
lactam antibiotics (third generation cephalosporins, e.g., ceftriaxone; carbapenems), fluoroquinolones 
and aminoglycosides should also be considered [3,5,25,26]. The group of β-lactam antibiotics is 
especially important, because in several vulnerable patient populations (children, pregnant women, 
patients with liver/kidney failure), there drugs are the first-choice agents, due to the debilitating side 
effect-profile of the alternate drugs [27]. Extended-spectrum β-lactamases (ESBLs) are plasmid-
encoded enzymes, capable of hydrolyzing penicillin-derivatives and cephalosporins (including third 
and fourth generation cephalosporins); in contrast, AmpC-type β-lactamases are mostly 
chromosomally-encoded (although they have also been described on plasmids), capable of 
hydrolyzing penicillin-derivatives and cephalosporins (including third generation cephalosporins 
and aztreonam, but not fourth generation cephalosporins). ESBLs are mainly Ambler Class A 
enzymes, that are inhibited by “first-generation” β-lactamase-inhibitors (such as clavulanic acid or 
sulbactam), while AmpC enzymes are Class C enzymes that are not inhibited by these adjuvants [28–
33]. Among Enterobacteriaceae, the prevalence of ESBLs and plasmid-encoded AmpCs are the highest 
in Klebsiella spp. and E. coli [34]. Additionally, Klebsiella species have shown to be great vectors for 
these plasmids and they provide a suitable genetic environment to mutations [28–33]. Since the 2000s, 
blaCTX-M-type ESBLs are the most prevalent around the globe, while blaTEM and blaSHV-type enzymes 
have become less relevant over time [28–33,35,36]. Due to their transmissibility, ESBLs are considered 
a serious public health/infection control issue, especially because these enzymes are encoded on 
larger-sized plasmids, which may additionally include resistance determinants for aminoglycosides 
and/or fluoroquinolones [28,37]. ESBL-producers have been associated with increased morbidity and 
mortality, particularly in intensive care units and in severely immunocompromised patients [38–40]. 
In UTIs with an ESBL-producing isolate (coupled with other resistance mechanisms), carbapenems 
essentially remain the only safe drug choice, while other “last resort” agents (e.g., tigecycline, colistin, 
ceftazidime-avibactam) are rarely used, due to their price, pharmacokinetic profile or side effects. 
Multidrug resistance (MDR) in Gram-negative bacteria is a growing concern, and the treatment of 
UTIs is increasingly complex challenge for clinicians [25,41–44]. These uropathogens may be resistant 
to a wide range of available drugs, necessitating the use of drugs that are only available in 
intravenous formulations, limiting the care of these patients to inpatient setting or outpatient 
parenteral antimicrobial therapy (OPAT), if available [45,46]. 
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Various national- and international-level surveillance programs are evaluating and publishing 
the resistance trends of various Gram-positive and Gram-negative bacteria [6,9,14,47–52]. 
Nevertheless, the epidemiology and antibiotic-susceptibility patterns of urinary tract pathogens vary 
greatly by region therefore, the assessment of local data is essential to evaluate trends over time and 
to reflect on the national situation, compared to international data, using the methods of analytical 
epidemiology [6,9,14,47–52]. Additionally, knowledge of the relevant antibiotic-susceptibility 
patterns of the major bacterial pathogens for UTIs is of utmost importance to allow for the optimal 
choice for antibiotic therapy [53,54]. The aim of this study was to assess and compare the resistance 
trends and epidemiology of E. coli and Klebsiella species in inpatients and outpatients at the Albert 
Szent-Györgyi Clinical Center (Szeged, Hungary) retrospectively, during a 10-year study period. 
2. Materials and Methods 
2.1. Study Design, Data Collection 
This retrospective study was carried out using microbiological data collected from the period 
between the 1st of January 2008 and 31st of December 2017 at the Institute of Clinical Microbiology 
(University of Szeged), which is the affiliated diagnostic microbiology laboratory of the Albert Szent-
Györgyi Clinical Center, a primary- and tertiary-care teaching hospital in the Southern Great Plain of 
Hungary. The Clinical Center has a bed capacity of 1820-beds (1465 active and 355 chronic beds, 
respectively) and annually serves more than 400,000 patients in the region, according to the data of 
the Hungarian National Health Insurance Fund (NEAK), including GP-level care, all the way to 
specialized medical interventions (Figure 1) [55]. Electronic search in the records of the MedBakter 
laboratory information system (LIS) for urine samples positive for E. coli and Klebsiella species was 
conducted by the authors (M.G., Á.M. and A.L.). 
 
Figure 1. Study site in Hungary (Southern Great Plain of Hungary: in blue; Albert Szent-Györgyi 
Clinical Center, Szeged: in green). 
Samples with clinically significant colony counts for the abovementioned bacteria (105 < colony 
forming units [CFU]/mL; however, this was subject to interpretation, based on the information 
provided on the request forms for microbiological analysis and relevant international guidelines, e.g., 
presence of underlying conditions in the genitourinary tract) were included in the data analysis. Only 
the first isolate per patient was included in the study, however, isolates with different antibiotic-
susceptibility patterns were considered as different individual isolates. In addition, patient data was 
also collected, that were limited to demographic characteristics (age and sex). The study was deemed 
exempt from ethics review by the Institutional Review Board, and informed consent was not required 
as data anonymity was maintained. 
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2.2. Identification of Isolates 
10 µL of each un-centrifuged urine sample was cultured on UriSelect chromogenic agar plates 
(Bio-Rad, Berkeley, CA, USA) with a calibrated loop, according to the manufacturer’s instructions 
and incubated at 37 °C for 24–48 h, aerobically. If the relevant pathogens presented in significant 
colony count, the plates were passed on for further processing. Between 2008–2012, presumptive 
phenotypic (biochemical reaction-based) methods and VITEK 2 ID (bioMérieux, Marcy-l’Étoile, 
France) were used for bacterial identification, while after 2013, this was complemented by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Bruker 
Daltonik Gmbh. Gr., Bremen, Germany). The methodology of sample preparation for MALDI-TOF 
MS measurements was described elsewhere [56–58]. Mass spectrometry was performed by the 
Microflex MALDI Biotyper (Bruker Daltonics, Bremen, Germany) in positive linear mode across the 
m/z range of 2 to 20 kDa; for each spectrum, 240 laser shots at 60 Hz in groups of 40 shots per sampling 
area were collected. The MALDI Biotyper RTC 3.1 software (Bruker Daltonics) and the MALDI 
Biotyper Library 3.1 were used for spectrum analysis. 
2.3. Antimicrobial Susceptibility Testing 
Antimicrobial susceptibility testing (AST) was performed using the Kirby–Bauer disk diffusion 
method and when appropriate, E-test (Liofilchem, Abruzzo, Italy) on Mueller–Hinton agar (MHA) 
plates. In addition, for the verification of discrepant results, VITEK 2 AST (bioMérieux, Marcy-
l’Étoile, France) was also used. The interpretation of the results was based on EUCAST breakpoints. 
Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212, Proteus mirabilis ATCC 35659, 
Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 700603 and Pseudomonas aeruginosa ATCC 
27853 were used as quality control strains. 
To evaluate the resistance trends of isolated strains, ciprofloxacin (CIP), ceftriaxone (CRO), 
meropenem (MER), gentamicin (GEN), sulfamethoxazole/trimetoprim (SXT) and nitrofurantion 
(NIT; relevant in case of E. coli) were chosen as indicator antibiotics, based on local antibiotic 
utilization data [59,60]. In addition, susceptibility data for fosfomycin (FOS) was also available for 
the second half (2013–2017) of the study period. FOS susceptibility testing was not routinely 
performed, only per request of the clinicians or in cases of extensive drug resistance. During data 
analysis, intermediately-susceptible results were grouped with and reported as resistant. 
If extended-spectrum beta-lactamase (ESBL)-production was suspected, detection was carried 
out based on EUCAST recommendations; since 2011, using AmpC-ESBL Detection Set (MAST 
Diagnostica GmbH, Reinfeld, Germany) and VITEK 2 AST (bioMérieux, Marcy-l’Étoile, France), 
according to the manufacturer’s instructions. Carbapenemase-production was suspected in case of 
reduced susceptibility or resistance to MER, these isolates were sent to a reference laboratory for 
further processing. 
2.4. Statistical Analysis 
Descriptive statistical analysis (including means or medians with ranges and percentages to 
characterize data) was performed using Microsoft Excel 2013 (Redmond, WA, USA, Microsoft Corp.). 
Statistical analyses were performed with SPSS software version 24 (IBM SPSS Statistics for Windows 
24.0, Armonk, NY, USA, IBM Corp.), using the χ2-test, Student’s t-test and Mann–Whitney U test. 
The normality of variables was tested using Shapiro–Wilk tests. p values < 0.05 were considered 
statistically significant. 
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3. Results 
3.1. Demographic Characteristics, Sample Types 
The median age of affected patients was 52 years (range: 0.3–97) in the outpatient group with a 
female-to-male ratio of 3.62 (78.34% female), while in the inpatient group, these values were 71 years 
(range: 0.4–96) and 2.42 (70.75% female), respectively. The detailed age distribution of patients in both 
affected patient groups is presented in Figure 2. The difference in the age distribution of the two 
patient groups was statistically significant (p < 0.0001). Among the affected patients, the age groups 
under 10 years of age (outpatients: 18.04%, inpatients: 13.80%) and over 60 years of age (outpatients: 
42.44%, outpatients: 68.04%) were the most numerous. All (100%) samples received from outpatient 
clinics were voided (midstream) urine, while the sample distribution from the inpatient departments 
was the following: midstream urine (46.72%) catheter-specimen urine (45.56%), first-stream urine 
(7.41%) and samples obtained through suprapubic bladder aspiration (0.31%). 
 
Figure 2. Age distribution of the affected patients in the outpatient and inpatient groups. 
3.2. Epidemiology of Escherichia coli and Klebsiella spp. Isolates 
During the 10-year study period (1 January 2008–31 December 2017), the Institute of Clinical 
Microbiology received 21,150 urine samples from outpatient clinics and 19,325 samples from 
inpatient departments that turned out to be positive for a significant urinary pathogen. Out of the 
positive urine samples, E. coli represented the overwhelming majority of all positive urine samples; 
56.75 ± 4.86% (range: 46.83–65.98%, lowest in 2008, highest in 2010) for outpatients, while 42.29 ± 
2.94% (range: 37.19–45.73%, lowest in 2015, highest in 2010) for inpatients. K. pneumoniae was isolated 
in 8.96 ± 2.29% (range: 2.97–10.37%, lowest in 2012, highest in 2011) for outpatients, while 13.41 ± 
2.20% (range: 9.54–15.25%, lowest in 2008, highest in 2011) for inpatient isolates; the isolation rate for 
K. oxytoca was 1.44 ± 0.34% (range: 0.74–1.77%, lowest in 2008, highest in 2011) for outpatients, and 
1.16 ± 0.22% (range: 0.74–1.77%, lowest in 2008, highest in 2011) for inpatients. There was significant 
difference in the isolation frequency of E. coli (p = 0.0002) and K. pneumoniae (p = 0.0003) when 
comparing inpatient and outpatient isolates, while only a numerical tendency could be observed for 
K. oxytoca (p > 0.05). The epidemiology and total species distribution of outpatient and inpatient 
samples is presented in Figure 3. 
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Figure 3. Frequency and species distribution of relevant isolates in inpatient and outpatient samples 
(2008–2017); IP: inpatient; OP: outpatient. 
3.3. Antibiotic-Susceptibility Trends among Isolates 
The resistance trends of the isolates E. coli and Klebsiella spp. against ciprofloxacin (CIP), 
ceftriaxone (CRO), gentamicin (GEN), sulfamethoxazole-trimethoprim (SXT), nitrofurantoin (NIT, 
relevant in case of E. coli) and the ratio of ESBL-producers (relevant since 2011) during the 10-year 
surveillance period are presented in Tables 1 and 2, and Figure 4 (E. coli) and Figure 5. (Klebsiella 
spp.). Overall, the highest levels of resistance in E. coli and Klebsiella spp. were detected against CIP 
and SUM. The ratio of resistant E. coli strains in the inpatient group were significantly higher to CIP, 
GEN and CRO (p = 0.0003, p < 0.0001 and p = 0.0003, respectively), but not in case of NIT and FOS (p 
> 0.05; Figure 4). In addition, E. coli resistance levels to the indicator antibiotics were significantly 
higher (p < 0.05) in the second half (2013–2017) of the study period in case of every drug (apart from 
CRO resistance in the outpatient samples and NIT, where resistance levels were significantly higher 
in the first five-year-period; Table 1; Figure 4). 
Table 1. Percentage of resistant E. coli strains to indicator antibiotics from inpatient and outpatient 
departments (2008–2017). 
 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Statistics 
CIP R% 
Outpatient 13.28 16.12 21.53 21.80 19.13 21.64 21.31 25.57 25.69 25.95 
p = 0.0003 
Inpatient 20.19 23.62 26.85 33.42 37.28 38.41 34.73 40.60 40.41 33.25 
NIT R% 
Outpatient 4.99 7.33 12.37 9.00 6.06 3.05 3.59 3.12 2.42 1.03 n.s.  
(p = 0.264) Inpatient 7.98 12.39 20.81 17.57 7.36 3.34 5.04 2.76 2.05 1.39 
GEN R% 
Outpatient 3.17 5.77 6.35 7.51 5.58 4.54 6.37 7.76 5.16 6.88 
p < 0.0001 
Inpatient 7.82 8.75 11.68 14.62 16.69 19.84 17.01 17.85 18.21 13.10 
SUM R% 
Outpatient 21.44 22.16 23.61 25.32 20.87 24.69 24.82 26.68 24.88 28.08 n.s.  
(p = 0.189) Inpatient 25.82 22.45 21.34 25.55 11.62 35.29 34.83 36.24 39.08 28.21 
CRO R% 
Outpatient 8.99 7.74 7.55 7.33 5.58 6.46 8.57 9.56 8.85 9.70 
p = 0.0003 
Inpatient 6.10 12.39 16.24 18.55 20.48 26.99 40.94 25.19 30.41 20.03 
ESBL% 
Outpatient 
 
6.31 4.33 5.50 6.94 9.15 7.32 9.02 
p = 0.0028 
Inpatient 8.85 10.59 25.72 38.97 23.06 29.08 18.39 
Values in italics represent the lowest resistance levels, boldface (peak) values correspond to the 
highest resistance levels in the study period; n.s.: not significant. 
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For the statistical analysis of resistance trends, K. pneumoniae and K. oxytoca isolates were 
grouped together as Klebsiella spp., as K. oxytoca represented only a minority (~1–1.5%) of isolates; in 
addition, after a preliminary analysis of the resistance trends among these two species, no differences 
(statistical or otherwise) could be observed. For Klebsiella spp., ratio of resistant strains in the inpatient 
group were significantly higher to GEN only (p = 0.0002; Figure 5). Resistance levels to the indicator 
antibiotics in Klebsiella spp. of inpatient origin were significantly higher (p < 0.05) in the second half 
(2013–2017) of the study period in case of every drug, while no similar trend was observed for the 
outpatient samples (Table 2). Regarding the outpatient isolates, the resistance levels of Klebsiella spp. 
were significantly higher, compared to E. coli to all antibiotics, except for SXT (CIP: p < 0.0001; GEN: 
p < 0.0001; CRO p = 0.0003), while during the analysis of inpatient samples, no similar trends were 
observed (p > 0.05). 
 
Figure 4. Resistance levels of Escherichia coli isolates from inpatient and outpatient urinary tract 
infections, expressed in the percentage (%) of resistant isolates. Asterisk (***): p < 0.001; n.s.: not 
significant; CIP: ciprofloxacin; NIT: nitrofurantoin; GEN: gentamicin; SUM: 
sulfamethoxazole/trimethoprim; CRO: ceftriaxone; ESBL: extended-spectrum β-lactamase-producing 
isolates. 
Table 2. Percentage of resistant Klebsiella spp. strains to indicator antibiotics from inpatient and 
outpatient departments (2008–2017). 
 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Statistics 
CIP R% 
Outpatient 37.31 41.48 45.16 35.47 40.77 40.38 33.03 38.78 31.60 34.08 n.s.  
(p = 0.641) Inpatient 23.40 30.00 35.10 37.50 34.28 35.76 48.40 45.57 38.18 37.45 
GEN R% 
Outpatient 27.69 34.09 25.81 24.53 27.69 27.40 21.10 28.14 18.80 19.10 
p = 0.0002 
Inpatient 26.24 13.33 14.42 13.31 16.96 15.41 17.99 16.14 16.36 13.62 
SUM R% 
Outpatient 25.38 39.77 33.33 35.00 33.08 35.58 37.61 39.16 32.80 37.45 n.s.  
(p = 0.399) Inpatient 27.66 21.67 34.62 30.24 23.43 29.07 43.15 43.99 36.06 35.74 
CRO R% 
Outpatient 23.85 31.25 37.63 26.74 36.15 35.10 27.52 35.36 27.20 25.09 
p = 0.132 
Inpatient 23.40 21.11 17.31 20.56 23.67 19.77 41.98 28.48 38.18 25.79 
ESBL% Outpatient  26.74 30.00 31.73 25.69 34.22 26.00 23.22 p = 0.243 
Inpatient 10.89 13.43 18.60 33.53 28.48 36.06 23.36 
Values in italics represent the lowest resistance levels, boldface (peak) values correspond to the 
highest resistance levels in the study period; n.s.: not significant. 
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Figure 5. Resistance levels of Klebsiella spp. isolates from inpatient and outpatient urinary tract 
infections, expressed in the percentage (%) of resistant isolates. Asterisk (***): p < 0.001; n.s.: not 
significant; CIP: ciprofloxacin; NIT: nitrofurantoin; GEN: gentamicin; SUM: 
sulfamethoxazole/trimethoprim; CRO: ceftriaxone; ESBL: extended-spectrum β-lactamase-producing 
isolates. 
ESBL-positivity (or simultaneous ESBL and AmpC-positivity) was detected in 6.94 ± 1.76% of 
outpatient and 22.09 ± 10.57% of inpatient E. coli isolates (p = 0.0028); in Klebsiella spp., these ratios 
were 28.23 ± 3.87% for outpatient and 23.36 ± 9.73% for inpatient isolates (p = 0.243). As of 2013, FOS 
susceptibility testing was performed for 15.63% of E. coli and 16.34% of Klebsiella spp. isolates in the 
inpatient group, while for outpatient isolates, 5.67% of E. coli and 17.77% of Klebsiella spp. were tested. 
Regarding inpatient samples, resistance to FOS was present in 14.66% of E. coli and 23.47% of Klebsiella 
spp., while in outpatient samples, this was 8.89% for E. coli (p = 0.0035) and 15.92% for Klebsiella spp. 
(p = 0.047), respectively. In outpatient samples, six individual isolates were detected which were 
intermediate/resistant to MER (one in 2009, 2011, 2014 and 2016, and two isolates in 2017; 
representing 2 E. coli and 4 K. pneumoniae isolates): one MER-intermediate isolate was resistant to all 
indicator antibiotics (but susceptible to colistin), while 5 out of 6 were susceptible to GEN and FOS, 
and 4 out of 6 were susceptible to SXT. In inpatient samples, eight such isolates were detected (one 
in 2011 and 2013, and two isolates in 2015, 2016 and 2017, respectively; representing 3 E. coli and 5 K. 
pneumoniae isolates). All relevant isolates were susceptible to GEN, 6 out of 8 were susceptible to FOS, 
while 4 out of 8 were susceptible to SXT. Most isolates intermediate/resistant to carbapenems were 
also resistant to CIP (in both patient groups). 
4. Discussion 
E. coli and Klebsiella species are the most common cause of urinary tract infections (UTIs) in both 
community and healthcare settings [1,3,4,6,9,14,47–52]. This was further proven in the context of our 
study, as E. coli was isolated in ~46–66%, and Klebsiella spp. was isolated in ~3–16% of cases. Their 
relatively lower prevalence in inpatient isolates is attributable to the more pronounced diversity in 
the causative agents of nosocomial UTIs, however, their clinical relevance should not be disregarded 
in either settings. In line with international literature, there was a predominance of females and 
patients over 50 years of age, among the affected population [1,3,4,6,9,14,47–52]. 
Regarding the local resistance levels, the results of the 10-year survey showed that there has 
been a pronounced increase in the resistance rates of several antibiotics by the second half of the 
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study period (2013–2017); in contrast, resistance levels of NIT in E. coli decreased. There was no single 
underlying event found that may be responsible for this local advantageous change in NIT resistance 
levels, although due to the extended and favoured use of fluoroquinolones and the inability to access 
NIT—both at the Albert Szent-Györgyi Clinical Center and in the country in the recent years—may 
have had a notable role. Henceforth, the role of NIT may have a renaissance in the therapy of 
uncomplicated UTIs [61,62]. The comparison of our results with the surveillance data of the European 
Antimicrobial Resistance Surveillance Network (EARS-Net, [63]) for the relevant time periods is 
presented in Table 3. 
Table 3. Comparison of the resistance data obtained in this study with the surveillance data of EARS-
Net. 
 Local Resistance 
Data (2008–2012) 
EARS-Net 
Surveillance 
Data for 
Hungary; 
2012 [63] 
Local 
Resistance 
Data (2013–
2017) 
EARS-Net 
Surveillance Data for 
Hungary; 2017 [63] 
3rd generation 
cephalosporins 
E. coli 5.58–26.99% 17.40% 6.46–40.94% 20.10% 
Klebsiella spp. 17.31–37.63% 43.00% 19.77–35.36% 41.10% 
Fluoroquinolones 
E. coli 13.28–21.80% 28.90% 21.31–25.95% 30.60% 
Klebsiella spp. 23.40–45.16% 41.60% 31.60–48.40% 41.45% 
Aminoglycosides 
E. coli 3.17–16.69% 15.10% 4.54–19.84% 17.10% 
Klebsiella spp. 13.31–34.09% 37.80% 18.80–27.40% 41.50% 
Carbapenems 
E. coli <0.05% <0.05% <0.05% 0.10% 
Klebsiella spp. <0.05% 0.30% <0.05% 0.30% 
Values in italics represent resistance levels that were lower than the national average. 
Some of the most concerning developments is the resistance in Klebsiella species to 3rd 
generation cephalosporins (exemplified by ceftriaxone in this survey), where even the lowest levels 
of resistance were around 15% in the outpatient group and close to 40% in the inpatient group. ESBL 
production has been observed in large percentage of urinary isolates in this study, especially in 
Klebsiella species. Some difference could be observed in the ratio of ESBL-positive and CRO-resistant 
strains (0.42–9.90% for E. coli and 0–10.25% for Klebsiella spp., respectively); this may be due to the 
fact that CRO resistance may also occur due to ESBL-independent mechanisms, such as AmpCs or 
other β-lactamases, overexpression of efflux pumps, changes in membrane permeability or porin 
mutations [64–66]. As ESBLs were the only one with public health/infection control significance in 
our hospital, the exact mechanism of resistance in this minor group of CRO-resistant isolates was not 
characterized further [34]. There was a significant difference in the rate of ESBL-positivity in E. coli 
among inpatient and outpatient isolates, however, no such different was observed for Klebsiella. 
ESBL-producing isolates have first been detected in nosocomial settings, nevertheless, after the 2000s, 
this demarcation line exist less and less [29,36]. In Hungary (and specifically in the southern region 
of the country), the blaCTX-M group is the most prevalent, which is associated with carrying resistance 
determinants to quinolones and aminoglycosides in addition to the relevant β-lactam antibiotics [67]. 
UTIs caused by these strains cannot be treated with the “conventional” β-lactam antibiotics 
(penicillin, cephalosporins), but carbapenems remain as a part of the antibiotic armamentarium 
[68,69]. However, the overuse of these drugs will inevitably lead to selection pressure (the prevalence 
of carbapenemase-producing Enterobacteriaceae (or CRE) is steadily increasing worldwide). Hungary 
is currently known to be a low-prevalence country for CRE (most of the isolates carry VIM- or OXA-
48-like enzymes), however, most of the isolates originate from UTIs [70,71]. 
Similarly, high levels of resistance to fluoroquinolone antibiotics have been reported for 
Enterobacteriaceae in regions where no restrictions were introduced to their use in the community and 
they are still considered to be first-line agents. If the Hungarian antibiotic utilization trends are 
considered, the country is doing well quantitatively (i.e., the amount of antibiotics consumed), 
however, a qualitative analysis (i.e., targeted therapy) reveals a much bleaker picture: the use of 
broad-spectrum antimicrobials (including fluoroquinolones) is significantly higher than in 
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Scandinavian countries, which may also correspond to the development of local resistance trends 
(based on the data of a Hungarian study group and European Surveillance of Antimicrobial 
Consumption Network; ESAC-Net) [59,60,72,73]. Some novel antibiotics, that recently received 
marketing authorization (for example, delafloxacin, ceftolozane-tazobactam, ceftazidime-avibactam) 
may aid the therapy of resistant Gram-negative infections; nevertheless, due to their prohibitive price 
and the limited clinical experience associated with these drugs, it is unknown when will they be 
considered in routine therapeutic protocols [42,74,75]. The increase in resistance is not only forcing 
changes in treatment guidelines and issues in the clinic, but also to poor prognoses, decreased QoL 
and an increase in the mortality rate of patients, especially in nosocomial settings [5]. E. coli and K. 
pneumoniae are major pathogens of nosocomial infections, including UTIs, that is frequently 
associated with resistance to the critically important antimicrobials. The WHO has recently published 
a priority list of resistant pathogens, where Escherichia coli and Klebsiella species resistant to third 
generation cephalosporins and carbapenems represent top-priority [76]. 
Some limitations of this study must be acknowledged: firstly, the design of the study is 
retrospective and there has been an inability to access the medical records of the individual patients 
affected by these infections. For this reason, the correlation between the existence of relevant risk 
factors and underlying illnesses (apart from age and inpatient/outpatient status) and the E. 
coli/Klebsiella spp. UTIs could not be assessed. The age-associated incidence in isolation of these 
pathogens may also reflect (at least in part) the high rate of bacteriuria in the elderly population 
(especially in catheterized patients) [77]. There is a risk of selection bias, as studies describing the 
prevalence of infectious diseases and resistance trends are mainly tertiary-care centers, which 
generally correspond to patients with more severe conditions or underlying illnesses. Finally, the 
molecular characterization of the resistance determinants in the individual isolates was not 
performed, only to the extent of presence/absence of ESBLs [78,79]. 
5. Conclusions 
This study presents the epidemiological trends and resistance levels of E. coli and Klebsiella 
species, the main pathogens associated with urinary tract infections (UTIs) in Hungary, over a long 
surveillance period (10 years), mainly demonstrating an increasing tendency regarding the resistance 
levels to various antibiotics. To the best of our knowledge, this is the longest-spanning study 
reporting on the prevalence and susceptibility patterns of these pathogens (and UTIs caused by these 
uropathogens by proxy) in Hungary. Their significantly higher prevalence in female patients with 
advanced age and instrumentation/catheterization and is in line with the findings in the literature. 
The type of setting (inpatient/outpatient) also had an effect on their isolation frequency, as there was 
a predominance of E. coli in uncomplicated UTIs, while in the inpatient setting, more relevant 
pathogens may be implicated. 
In addition to patient history, drug allergies and national/institutional drug availability, the 
choice of empiric antibiotic therapy should be selected based on local susceptibility profiles or a 
cumulative hospital antibiogram, based on the guidelines of the Infectious Diseases Society of 
America (IDSA); nonetheless, the choice of antimicrobial drugs should be revised after the specific 
antibiogram for the relevant urinary pathogen has become available. The data in this study may aid 
the creation of a local/hospital antibiogram or a national surveillance system for urinary tract 
pathogens in Hungary. 
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